1. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
- Author
-
Cingolani, A., Tummolo, A. M., Montemurro, G., Gremese, E., Larosa, L., Cipriani, M. C., Pasciuto, G., Liperoti, R., Murri, R., Pirronti, T., Cauda, R., Fantoni, M., Bellieni, A., Brandi, V., Calabrese, A., Calvello, M. R., Ciccullo, A., Corbo, G., Falsiroli, C., Intini, E., Landi, G., Leone, P. M., Macagno, F., Martis, I., Pais, C., Potenza, A., Salini, S., Simonetti, J., Taddei, E., Tosato, M., Varone, F., Ventura, G., and Siciliano, M.
- Subjects
0301 basic medicine ,Male ,Baricitinib ,medicine.medical_treatment ,Azithromycin ,Lopinavir ,0302 clinical medicine ,Respiratory function ,030212 general & internal medicine ,Sulfonamides ,Brief Report ,General Medicine ,Drug Combinations ,Infectious Diseases ,Treatment Outcome ,Radiological weapon ,Anesthesia ,Acute Disease ,Immunotherapy ,Coronavirus Infections ,Respiratory Insufficiency ,medicine.drug ,Hydroxychloroquine ,Microbiology (medical) ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Pneumonia, Viral ,Antibodies, Monoclonal, Humanized ,Antiviral Agents ,03 medical and health sciences ,Betacoronavirus ,medicine ,Humans ,Pandemics ,Aged ,Ritonavir ,business.industry ,SARS-CoV-2 ,Sarilumab ,Drug Repositioning ,COVID-19 ,Respiratory failure ,Purines ,Azetidines ,Pyrazoles ,business - Abstract
A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.
- Published
- 2020